Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 274


Overcoming malignant cell-based mechanisms of resistance to immune checkpoint blockade antibodies.

Ajina R, Zahavi DJ, Zhang YW, Weiner LM.

Semin Cancer Biol. 2019 Dec 19. pii: S1044-579X(19)30401-8. doi: 10.1016/j.semcancer.2019.12.005. [Epub ahead of print] Review.


Implementation of the Smoking Treatment and Recovery (STAR) program: healthy cancer survivorship through integrated tobacco control.

Taylor KL, Fallon S, Subramaniam D, Davis K, To C, Lobo T, Tercyak KP, Friberg J, Tynan M, Russell E, Ahmed W, Ponder MC, Cusaac L, Thompson J, Gardner K, Kim C, Weiner LM.

J Cancer Surviv. 2019 Nov 4. doi: 10.1007/s11764-019-00826-1. [Epub ahead of print]


Tumor mechanisms of resistance to immune attack.

Zahavi DJ, Weiner LM.

Prog Mol Biol Transl Sci. 2019;164:61-100. doi: 10.1016/bs.pmbts.2019.03.009. Epub 2019 Apr 3.


SpCas9-expression by tumor cells can cause T cell-dependent tumor rejection in immunocompetent mice.

Ajina R, Zamalin D, Zuo A, Moussa M, Catalfamo M, Jablonski SA, Weiner LM.

Oncoimmunology. 2019 Mar 16;8(5):e1577127. doi: 10.1080/2162402X.2019.1577127. eCollection 2019.


CancerInSilico: An R/Bioconductor package for combining mathematical and statistical modeling to simulate time course bulk and single cell gene expression data in cancer.

Sherman TD, Kagohara LT, Cao R, Cheng R, Satriano M, Considine M, Krigsfeld G, Ranaweera R, Tang Y, Jablonski SA, Stein-O'Brien G, Gaykalova DA, Weiner LM, Chung CH, Fertig EJ.

PLoS Comput Biol. 2019 Apr 19;14(4):e1006935. doi: 10.1371/journal.pcbi.1006935. eCollection 2018 Jun.


Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy.

Zahavi DJ, Weiner LM.

Int J Mol Sci. 2019 Jan 4;20(1). pii: E158. doi: 10.3390/ijms20010158. Review.


A Mechanism of Resistance to Antibody-Targeted Immune Attack.

Aldeghaither DS, Zahavi DJ, Murray JC, Fertig EJ, Graham GT, Zhang YW, O'Connell A, Ma J, Jablonski SA, Weiner LM.

Cancer Immunol Res. 2019 Feb;7(2):230-243. doi: 10.1158/2326-6066.CIR-18-0266. Epub 2018 Dec 18.


Hospital microbiology laboratory practices for Enterobacteriaceae: Centers for Disease Control and Prevention National Healthcare Safety Network (NHSN) annual survey, 2015 and 2016.

Shugart A, Walters MS, Weiner LM, Lonsway D, Kallen AJ.

Infect Control Hosp Epidemiol. 2018 Sep;39(9):1115-1117. doi: 10.1017/ice.2018.153. Epub 2018 Jul 24.


Functional genomics: paving the way for more successful cancer immunotherapy.

Ajina R, Zamalin D, Weiner LM.

Brief Funct Genomics. 2019 Mar 22;18(2):86-98. doi: 10.1093/bfgp/ely017. Review.


Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion.

Chaganty BKR, Qiu S, Gest A, Lu Y, Ivan C, Calin GA, Weiner LM, Fan Z.

Cancer Lett. 2018 Aug 28;430:47-56. doi: 10.1016/j.canlet.2018.05.009. Epub 2018 May 8.


Plac1 Is a Key Regulator of the Inflammatory Response and Immune Tolerance In Mammary Tumorigenesis.

Yuan H, Wang X, Shi C, Jin L, Hu J, Zhang A, Li J, Vijayendra N, Doodala V, Weiss S, Tang Y, Weiner LM, Glazer RI.

Sci Rep. 2018 Apr 9;8(1):5717. doi: 10.1038/s41598-018-24022-w.


Vital Signs: Containment of Novel Multidrug-Resistant Organisms and Resistance Mechanisms - United States, 2006-2017.

Woodworth KR, Walters MS, Weiner LM, Edwards J, Brown AC, Huang JY, Malik S, Slayton RB, Paul P, Capers C, Kainer MA, Wilde N, Shugart A, Mahon G, Kallen AJ, Patel J, McDonald LC, Srinivasan A, Craig M, Cardo DM.

MMWR Morb Mortal Wkly Rep. 2018 Apr 6;67(13):396-401. doi: 10.15585/mmwr.mm6713e1.


A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer.

Pishvaian MJ, Slack RS, Jiang W, He AR, Hwang JJ, Hankin A, Dorsch-Vogel K, Kukadiya D, Weiner LM, Marshall JL, Brody JR.

Cancer. 2018 Jun 1;124(11):2337-2346. doi: 10.1002/cncr.31309. Epub 2018 Mar 26.


Detection and characterization of a novel spotted fever group Rickettsia genotype in Haemaphysalis leporispalustris from California, USA.

Eremeeva ME, Weiner LM, Zambrano ML, Dasch GA, Hu R, Vilcins I, Castro MB, Bonilla DL, Padgett KA.

Ticks Tick Borne Dis. 2018 May;9(4):814-818. doi: 10.1016/j.ttbdis.2018.02.023. Epub 2018 Mar 1.


A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies.

Deeken JF, Wang H, Hartley M, Cheema AK, Smaglo B, Hwang JJ, He AR, Weiner LM, Marshall JL, Giaccone G, Liu S, Luecht J, Spiegel JY, Pishvaian MJ.

Cancer Chemother Pharmacol. 2018 Mar;81(3):587-596. doi: 10.1007/s00280-018-3533-8. Epub 2018 Feb 1.


RNA Interference Screening to Identify Proliferation Determinants in Breast Cancer Cells.

Zhang YW, Nasto RE, Jablonski SA, Serebriiskii IG, Surana R, Murray J, Johnson M, Riggins RB, Clarke R, Golemis EA, Weiner LM.

Bio Protoc. 2017;7(15). pii: e2435. doi: 10.21769/BioProtoc.2435. Epub 2017 Aug 5.


Pathogen Distribution and Antimicrobial Resistance Among Pediatric Healthcare-Associated Infections Reported to the National Healthcare Safety Network, 2011-2014.

Lake JG, Weiner LM, Milstone AM, Saiman L, Magill SS, See I.

Infect Control Hosp Epidemiol. 2018 Jan;39(1):1-11. doi: 10.1017/ice.2017.236. Epub 2017 Dec 18.


Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice.

Smith JP, Wang S, Nadella S, Jablonski SA, Weiner LM.

Cancer Immunol Immunother. 2018 Feb;67(2):195-207. doi: 10.1007/s00262-017-2077-9. Epub 2017 Oct 17.


Antifungal Susceptibility Testing Practices at Acute Care Hospitals Enrolled in the National Healthcare Safety Network, United States, 2011-2015.

Vallabhaneni S, Sapiano M, Weiner LM, Lockhart SR, Magill S.

Open Forum Infect Dis. 2017 Aug 16;4(4):ofx175. doi: 10.1093/ofid/ofx175. eCollection 2017 Fall.


An unbiased in vivo functional genomics screening approach in mice identifies novel tumor cell-based regulators of immune rejection.

Shuptrine CW, Ajina R, Fertig EJ, Jablonski SA, Kim Lyerly H, Hartman ZC, Weiner LM.

Cancer Immunol Immunother. 2017 Dec;66(12):1529-1544. doi: 10.1007/s00262-017-2047-2. Epub 2017 Aug 2.


Protein network construction using reverse phase protein array data.

Varghese RS, Zuo Y, Zhao Y, Zhang YW, Jablonski SA, Pierobon M, Petricoin EF, Ressom HW, Weiner LM.

Methods. 2017 Jul 15;124:89-99. doi: 10.1016/j.ymeth.2017.06.017. Epub 2017 Jun 24.


Predictive biomarkers for checkpoint inhibitor-based immunotherapy.

Gibney GT, Weiner LM, Atkins MB.

Lancet Oncol. 2016 Dec;17(12):e542-e551. doi: 10.1016/S1470-2045(16)30406-5. Review.


Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014.

Weiner LM, Webb AK, Limbago B, Dudeck MA, Patel J, Kallen AJ, Edwards JR, Sievert DM.

Infect Control Hosp Epidemiol. 2016 Nov;37(11):1288-1301. Epub 2016 Aug 30.


Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma.

Murakami S, Shahbazian D, Surana R, Zhang W, Chen H, Graham GT, White SM, Weiner LM, Yi C.

Oncogene. 2017 Mar 2;36(9):1232-1244. doi: 10.1038/onc.2016.288. Epub 2016 Aug 22.


Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer.

Beglyarova N, Banina E, Zhou Y, Mukhamadeeva R, Andrianov G, Bobrov E, Lysenko E, Skobeleva N, Gabitova L, Restifo D, Pressman M, Serebriiskii IG, Hoffman JP, Paz K, Behrens D, Khazak V, Jablonski SA, Golemis EA, Weiner LM, Astsaturov I.

Clin Cancer Res. 2016 Dec 15;22(24):6153-6163. Epub 2016 Jul 6.


Keratin-associated protein 5-5 controls cytoskeletal function and cancer cell vascular invasion.

Berens EB, Sharif GM, Schmidt MO, Yan G, Shuptrine CW, Weiner LM, Glasgow E, Riegel AT, Wellstein A.

Oncogene. 2017 Feb 2;36(5):593-605. doi: 10.1038/onc.2016.234. Epub 2016 Jul 4.


Policies for Controlling Multidrug-Resistant Organisms in US Healthcare Facilities Reporting to the National Healthcare Safety Network, 2014.

Weiner LM, Webb AK, Walters MS, Dudeck MA, Kallen AJ.

Infect Control Hosp Epidemiol. 2016 Sep;37(9):1105-8. doi: 10.1017/ice.2016.139. Epub 2016 Jun 28.


Vital Signs: Preventing Antibiotic-Resistant Infections in Hospitals - United States, 2014.

Weiner LM, Fridkin SK, Aponte-Torres Z, Avery L, Coffin N, Dudeck MA, Edwards JR, Jernigan JA, Konnor R, Soe MM, Peterson K, Clifford McDonald L.

Am J Transplant. 2016 Jul;16(7):2224-30. doi: 10.1111/ajt.13893.


Antibiotic Stewardship Programs in U.S. Acute Care Hospitals: Findings From the 2014 National Healthcare Safety Network Annual Hospital Survey.

Pollack LA, van Santen KL, Weiner LM, Dudeck MA, Edwards JR, Srinivasan A.

Clin Infect Dis. 2016 Aug 15;63(4):443-9. doi: 10.1093/cid/ciw323. Epub 2016 May 19.


G-DOC Plus - an integrative bioinformatics platform for precision medicine.

Bhuvaneshwar K, Belouali A, Singh V, Johnson RM, Song L, Alaoui A, Harris MA, Clarke R, Weiner LM, Gusev Y, Madhavan S.

BMC Bioinformatics. 2016 Apr 30;17(1):193. doi: 10.1186/s12859-016-1010-0.


Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer.

Tian X, Shivapurkar N, Wu Z, Hwang JJ, Pishvaian MJ, Weiner LM, Ley L, Zhou D, Zhi X, Wellstein A, Marshall JL, He AR.

Oncol Lett. 2016 Mar;11(3):1645-1650. Epub 2016 Jan 13.


Vital Signs: Preventing Antibiotic-Resistant Infections in Hospitals - United States, 2014.

Weiner LM, Fridkin SK, Aponte-Torres Z, Avery L, Coffin N, Dudeck MA, Edwards JR, Jernigan JA, Konnor R, Soe MM, Peterson K, McDonald LC.

MMWR Morb Mortal Wkly Rep. 2016 Mar 11;65(9):235-41. doi: 10.15585/mmwr.mm6509e1.


Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer.

Wu Z, Gabrielson A, Hwang JJ, Pishvaian MJ, Weiner LM, Zhuang T, Ley L, Marshall JL, He AR.

Cancer Chemother Pharmacol. 2015 Dec;76(6):1309-14. doi: 10.1007/s00280-015-2855-z. Epub 2015 Oct 27.


Antibody Engineering & Therapeutics 2015: The Antibody Society's annual meeting December 7-10, 2015, San Diego, CA.

Parren PW, Burton DR, Bradbury A, Huston JS, Carter PJ, Veldman T, Chester KA, Larrick JW, Alfenito MR, Scott JK, Weiner LM, Adams GP, Reichert JM.

MAbs. 2015;7(6):981-8. doi: 10.1080/19420862.2015.1089707. Epub 2015 Sep 30.


Cancer immunology for the clinician.

Weiner LM.

Clin Adv Hematol Oncol. 2015 May;13(5):299-306. Review.


Acquisition of estrogen independence induces TOB1-related mechanisms supporting breast cancer cell proliferation.

Zhang YW, Nasto RE, Varghese R, Jablonski SA, Serebriiskii IG, Surana R, Calvert VS, Bebu I, Murray J, Jin L, Johnson M, Riggins R, Ressom H, Petricoin E, Clarke R, Golemis EA, Weiner LM.

Oncogene. 2016 Mar 31;35(13):1643-56. doi: 10.1038/onc.2015.226. Epub 2015 Jul 13.


Mechanisms of action of therapeutic antibodies for cancer.

Redman JM, Hill EM, AlDeghaither D, Weiner LM.

Mol Immunol. 2015 Oct;67(2 Pt A):28-45. doi: 10.1016/j.molimm.2015.04.002. Epub 2015 Apr 23. Review.


Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2.

Zhu EF, Gai SA, Opel CF, Kwan BH, Surana R, Mihm MC, Kauke MJ, Moynihan KD, Angelini A, Williams RT, Stephan MT, Kim JS, Yaffe MB, Irvine DJ, Weiner LM, Dranoff G, Wittrup KD.

Cancer Cell. 2015 Apr 13;27(4):489-501. doi: 10.1016/j.ccell.2015.03.004.


Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies.

von Mehren M, Bookman M, Meropol NJ, Weiner LM, Sherman E, Li J, Knoblauch R, Parekh T, Cohen RB.

Cancer Chemother Pharmacol. 2015 May;75(5):1047-55. doi: 10.1007/s00280-015-2705-z. Epub 2015 Mar 20.


Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs.

AlDeghaither D, Smaglo BG, Weiner LM.

J Clin Pharmacol. 2015 Mar;55 Suppl 3:S4-20. doi: 10.1002/jcph.407. Review.


National Healthcare Safety Network report, data summary for 2013, Device-associated Module.

Dudeck MA, Edwards JR, Allen-Bridson K, Gross C, Malpiedi PJ, Peterson KD, Pollock DA, Weiner LM, Sievert DM.

Am J Infect Control. 2015 Mar 1;43(3):206-21. doi: 10.1016/j.ajic.2014.11.014. Epub 2015 Jan 6. No abstract available.


Antibody engineering and therapeutics conference. The annual meeting of the antibody society, Huntington Beach, CA, December 7-11, 2014.

Larrick JW, Parren P, Huston JS, Plückthun A, Bradbury A, Tomlinson IM, Chester KA, Burton DR, Adams GP, Weiner LM, Scott JK, Alfenito MR, Veldman T, Reichert JM.

MAbs. 2014;6(5):1115-23. doi: 10.4161/19420862.2014.971627.


c-Abl modulates tumor cell sensitivity to antibody-dependent cellular cytotoxicity.

Murray JC, Aldeghaither D, Wang S, Nasto RE, Jablonski SA, Tang Y, Weiner LM.

Cancer Immunol Res. 2014 Dec;2(12):1186-98. doi: 10.1158/2326-6066.CIR-14-0083. Epub 2014 Oct 9.


The development of immunoconjugates for targeted cancer therapy.

Smaglo BG, Aldeghaither D, Weiner LM.

Nat Rev Clin Oncol. 2014 Nov;11(11):637-48. doi: 10.1038/nrclinonc.2014.159. Epub 2014 Sep 30. Review.


IL4 limits the efficacy of tumor-targeted antibody therapy in a murine model.

Surana R, Wang S, Xu W, Jablonski SA, Weiner LM.

Cancer Immunol Res. 2014 Nov;2(11):1103-12. doi: 10.1158/2326-6066.CIR-14-0103. Epub 2014 Sep 9.


Stereotactic Body Radiation Therapy (SBRT) Combined With Chemotherapy for Unresected Pancreatic Adenocarcinoma.

Gurka MK, Kim C, He AR, Charabaty A, Haddad N, Turocy J, Johnson L, Jackson P, Weiner LM, Marshall JL, Collins SP, Pishvaian MJ, Unger K.

Am J Clin Oncol. 2017 Apr;40(2):152-157. doi: 10.1097/COC.0000000000000118.


Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy.

Kim B, Wang S, Lee JM, Jeong Y, Ahn T, Son DS, Park HW, Yoo HS, Song YJ, Lee E, Oh YM, Lee SB, Choi J, Murray JC, Zhou Y, Song PH, Kim KA, Weiner LM.

Oncogene. 2015 Feb 26;34(9):1083-93. doi: 10.1038/onc.2014.51. Epub 2014 Mar 24.


CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.

Gleason MK, Ross JA, Warlick ED, Lund TC, Verneris MR, Wiernik A, Spellman S, Haagenson MD, Lenvik AJ, Litzow MR, Epling-Burnette PK, Blazar BR, Weiner LM, Weisdorf DJ, Vallera DA, Miller JS.

Blood. 2014 May 8;123(19):3016-26. doi: 10.1182/blood-2013-10-533398. Epub 2014 Mar 20.


A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers.

Denlinger CS, Meropol NJ, Li T, Lewis NL, Engstrom PF, Weiner LM, Cheng JD, Alpaugh RK, Cooper H, Wright JJ, Cohen SJ.

Clin Colorectal Cancer. 2014 Jun;13(2):81-6. doi: 10.1016/j.clcc.2013.12.005. Epub 2014 Jan 4.


State of infection prevention in US hospitals enrolled in the National Health and Safety Network.

Stone PW, Pogorzelska-Maziarz M, Herzig CT, Weiner LM, Furuya EY, Dick A, Larson E.

Am J Infect Control. 2014 Feb;42(2):94-9. doi: 10.1016/j.ajic.2013.10.003.

Supplemental Content

Loading ...
Support Center